132714-97-7

Basic information

• Product Name: (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
• Synonyms: (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
• CAS NO: 132714-97-7
• Molecular Weight: 260.293
• Mol File: 132714-97-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione(132714-97-7)
• EPA Substance Registry System: (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione(132714-97-7)

Safety Data

• Hazardous Substances Data: 132714-97-7(Hazardous Substances Data)

Usage

General Description

(7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione is a chemical compound that belongs to the class of pyrrolopyrazine derivatives. It is a bicyclic structure containing a six-membered ring and a five-membered ring, along with a benzyl group and a hydroxy group. (7R,8aS)-2-benzyl-7-hydroxyhexahydropyrrolo[1,2-a]pyrazine-1,4-dione has potential biological activities and may be of interest in the field of medicinal chemistry, for example as a potential drug candidate. Its precise pharmacological properties and therapeutic applications are yet to be fully elucidated, but it may have potential as a pharmacological agent for various medical conditions. Further research and investigation are necessary to fully understand the properties and potential uses of this compound.

Upstream product

• 51-35-4 4R-4-hydroxyproline 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 132715-17-4 (2S,4R)-methyl 1-(2-chloroacetyl)-4-hydroxypyrrolidine-2-carboxylate 
• 100-46-9 benzylamine 

Downstream Products

• 132715-02-7 Phenyl-acetic acid (7R,8aS)-2-benzyl-1,4-dioxo-octahydro-pyrrolo[1,2-a]pyrazin-7-yl ester 
• 1429196-88-2 (7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[2-(trifluoromethyl)phenyl]-sulfonyl}octahydropyrrolo[1,2-a]pyrazine 
• 1429199-72-3 (7R,8aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-7-{[5-(trifluoromethyl)-pyridin-2-yl]oxy}octahydropyrrolo[1,2-a]pyrazine 
• 1429199-52-9 (7R,8aS)-7-{[5-(1-methylcyclopropyl)pyrazin-2-yl]oxy}-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydropyrrolo[1,2-a]pyrazine 
• 1429197-82-9 (7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(1,1-difluoroethyl)-phenyl]sulfonyl}octahydropyrrolo[1,2-a]pyrazine 
• 1429197-81-8 1-(3-{[(7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydropyrrolo[1,2-a]-pyrazin-2(1H)-yl]sulfonyl}phenyl)ethanone 
• 1429197-25-0 3-{ [(7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydropyrrolo[1,2-a]-pyrazin-2(1H)-yl]sulfonyl}-5-(trifluoromethyl)benzonitrile 
• 1429197-86-3 (7R,8aS)-2-{[3-bromo-5-(trifluoromethyl)phenyl]sulfonyl}-7-[(5-cyclopropylpyrazin-2-yl)oxy]octahydropyrrolo[1,2-a]pyrazine 
• 1429197-23-8 (7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[(2,4-difluorophenyl)-sulfonyl]octahydropyrrolo[1,2-a]pyrazine 
• 1429197-18-1 (7R,8aS)-2-[(3-tert-butyl-4-methoxyphenyl)sulfonyl]-7-[(5-cyclopropyl-pyrazin-2-yl)oxy]octahydropyrrolo[1,2-a]pyrazine 
• 1429295-25-9 [(7R,8aS)-7-[(5-chloropyridin-2-yl)oxy]hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl][3-(trifluoromethyl)phenyl]methanone 
• 1429295-24-8 [(7R,8aS)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl][3-(trifluoromethyl)phenyl]methanone 
• 1443034-63-6 [(7R,8aS)-7-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone 
• 1429199-84-7 (7R,8aS)-2-benzyl-7-[(5-cyclopropylpyrazin-2-yl)oxy]octahydropyrrolo[1,2-a]pyrazine 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS

The present application relates to: (a) compounds of Formula (I): (I), and salts thereof, wherein Z1, Z2, Z3, Z4, R1, R2, and R3 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel inhibitors.

8-Hydroxylated Derivatives of Diazabicyclononanes, 2,5-Dioxodiazabicyclononanes and Some Related Esters

Pharmacological considerations promted the authors to synthesize a series of 8-hydroxylated optically active derivatives of diazabicyclononanes and of their 2,5-dioxo analogs from trans-4-hydroxy-L-proline.Esterification with appropriate anhydrides led to the corresponding esters with 6S,8R configuration.Inversion of configuration at C-8 was performed using Mitsunobu method and led to the diastereoisomeric series of 6S,8S esters.A tentative pharmacological evaluation was carried out in the area of sedative and spasmolytic activities.